▎ 摘　　要

NOVELTY - A recombinant antibody comprising a light chain variable (VL) region and a heavy chain variable (VH) region, is new. USE - The recombinant antibody is useful for detecting coronavirus or determining whether a subject is infected by a coronavirus through a biological sample isolated from the subject. The coronavirus is SARS-coronavirus-2. The subject is a human (all claimed). The recombinant antibody also used for treating a coronavirus infection in a subject. ADVANTAGE - The recombinant antibody rapidly and accurately detects coronavirus infection in a short period of time. DETAILED DESCRIPTION - A recombinant antibody comprising a light chain variable (VL) region and a heavy chain variable (VH) region is new, where the VL region comprises a first complementarity determining region (CDR-L1), a second CDR (CDR-L2), and a third CDR (CDR-L3), and the VH region comprises a first CDR (CDR-H1), a second CDR (CDR-H2), and a third CDR (CDR-H3), where the CDR-L1, the CDR-L2, the CDR-L3, the CDR-H1, the CDR-H2, and the CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 7, 8, 9, 11, 12, and 13, the CDR-L1, the CDR-L2, the CDR-L3, the CDR-H1, the CDR-H2, and the CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 15, 16, 17, 19, 20, and 21, the CDR-L1, the CDR-L2, the CDR-L3, the CDR-H1, the CDR-H2, and the CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 23, 24, 25, 27, 28, and 29, the CDR-L1, the CDR-L2, the CDR-L3, the CDR-H1, the CDR-H2, and the CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 31, 32, 33, 35, 36, and 37, the CDR-L1, the CDR-L2, the CDR-L3, the CDR-H1, the CDR-H2, and the CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 39, 40, 41, 43, 44, and 45, the CDR-L1, the CDR-L2, the CDR-L3, the CDR-H1, the CDR-H2, and the CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 47, 48, 49, 51, 52, and 53, or the CDR-L1, the CDR-L2, the CDR-L3, the CDR-H1, the CDR-H2, and the CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 55, 56, 57, 59, 60, and 61. Asp-Val-Asn-Gly-Tyr-Val-Ala (SEQ ID NO: 7), Tyr-Phe-Thr-Ser-Ser-Leu-Tyr-Ser (SEQ ID NO: 8), His-Phe-Ser-Phe-Pro-Phe-Thr (SEQ ID NO: 9), Phe-Thr-Ile-Asn-Thr-Trp-Gly-Ile-His (SEQ ID NO: 11), Gly-Ile-Leu-Pro-Tyr-Gly-Gly-His-Ser-Asp (SEQ ID NO: 12), Ala-Thr-Leu-Met (SEQ ID NO: 13), Asp-Val-Ser-Ser-Ala-Val-Ala (SEQ ID NO: 15), Tyr-Thr-Thr-Asn-Trp-Leu-Leu-Ser (SEQ ID NO: 16), Phe-Tyr-Asp-Tyr-Pro-Ile-Thr (SEQ ID NO: 17), and Phe-Ser-Ile-Asp-Ala-Gly-Ala-Ile-His (SEQ ID NO: 19). INDEPENDENT CLAIMS are included for the following: 1. a kit comprising a first recombinant antibody and a second recombinant antibody chosen from the recombinant antibody; and 2. a method of determining whether a subject is infected by a coronavirus through a biological sample isolated from the subject involves detecting the presence or absence of a nucleocapsid protein of the coronavirus in the biological sample by use of the recombinant antibody, where the presence of the nucleocapsid protein indicates that the subject is infected by the coronavirus.